Music |
Video |
Movies |
Chart |
Show |
ASCO: Adjuvant Osimertinib for Resected EGFR-Positive Non-Small Cell Lung Cancer (PracticeUpdate) View | |
ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial (European Society for Medical Oncology (ESMO)) View | |
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer (ecancer) View | |
Reflections on the ADAURA study (VJOncology) View | |
ADAURA Trial; Early Stage Non–Small Cell Lung Cancer (OncLive) View | |
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer (ecancer) View | |
ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC (OncLive) View | |
Role of Adjuvant Osimertinib in Early Stage NSCLC (OncLive) View | |
ADAURA Trial: Tagrisso u0026 Resectable EGFR+ - Leading Developments u0026 Current Questions in Lung Cancer (GRACE - Global Resource for Advancing Cancer Education) View | |
ADAURA: osimertinib post-tumor resection in NSCLC (VJOncology) View |